NZ530943A - A fusion protein - Google Patents

A fusion protein

Info

Publication number
NZ530943A
NZ530943A NZ530943A NZ53094302A NZ530943A NZ 530943 A NZ530943 A NZ 530943A NZ 530943 A NZ530943 A NZ 530943A NZ 53094302 A NZ53094302 A NZ 53094302A NZ 530943 A NZ530943 A NZ 530943A
Authority
NZ
New Zealand
Prior art keywords
fusion protein
sil
molecule
functional
expression
Prior art date
Application number
NZ530943A
Other languages
English (en)
Inventor
Simon Arnett Jones
Nicholas Topley
Original Assignee
Univ Cardiff
Univ Wales Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff, Univ Wales Medicine filed Critical Univ Cardiff
Publication of NZ530943A publication Critical patent/NZ530943A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
NZ530943A 2001-08-03 2002-08-02 A fusion protein NZ530943A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119015.6A GB0119015D0 (en) 2001-08-03 2001-08-03 A fusion protein
PCT/GB2002/003581 WO2003014359A2 (en) 2001-08-03 2002-08-02 A fusion protein

Publications (1)

Publication Number Publication Date
NZ530943A true NZ530943A (en) 2005-09-30

Family

ID=9919793

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ530943A NZ530943A (en) 2001-08-03 2002-08-02 A fusion protein

Country Status (13)

Country Link
US (3) US20050064558A1 (ja)
EP (1) EP1412503B1 (ja)
JP (1) JP4360902B2 (ja)
KR (1) KR100870296B1 (ja)
AT (1) ATE419362T1 (ja)
AU (1) AU2002319524B2 (ja)
CA (1) CA2456183C (ja)
DE (1) DE60230627D1 (ja)
DK (1) DK1412503T3 (ja)
ES (1) ES2320862T3 (ja)
GB (1) GB0119015D0 (ja)
NZ (1) NZ530943A (ja)
WO (1) WO2003014359A2 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026353A2 (en) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Media for culturing stem cells
US9040297B2 (en) * 2006-08-02 2015-05-26 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
EA019512B1 (ru) * 2008-07-02 2014-04-30 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Il-6-опосредованная иммунотерапия
JP2010271181A (ja) * 2009-05-21 2010-12-02 Kenji Yamamoto Ｃｃｒ５を標的とする阻害剤の疾病治療効果、予防効果及び副作用を評価する方法
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
US9429463B2 (en) 2013-03-04 2016-08-30 International Road Dynamics, Inc. System and method for measuring moving vehicle information using electrical time domain reflectometry
EP2992898A1 (en) * 2014-09-04 2016-03-09 Klinikum rechts der Isar der Technischen Universität München T-cell adjuvant and its use for therapeutic or prophylactic vaccination

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5250836A (en) * 1989-12-20 1993-10-05 Fujitsu Limited Semiconductor device having silicon-on-insulator structure
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US20040170604A1 (en) * 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
WO2000001731A1 (fr) * 1998-07-06 2000-01-13 Tosoh Corporation Proteine fusionnee avec liaison directe du recepteur il-6 a il-6

Also Published As

Publication number Publication date
EP1412503B1 (en) 2008-12-31
ATE419362T1 (de) 2009-01-15
KR20040049838A (ko) 2004-06-12
KR100870296B1 (ko) 2008-11-25
CA2456183C (en) 2010-01-05
WO2003014359A3 (en) 2003-10-16
AU2002319524B2 (en) 2006-10-12
JP4360902B2 (ja) 2009-11-11
US20050064558A1 (en) 2005-03-24
JP2005502337A (ja) 2005-01-27
DE60230627D1 (de) 2009-02-12
WO2003014359A2 (en) 2003-02-20
US20090252705A1 (en) 2009-10-08
GB0119015D0 (en) 2001-09-26
ES2320862T3 (es) 2009-05-29
CA2456183A1 (en) 2003-02-20
US20070172458A1 (en) 2007-07-26
DK1412503T3 (da) 2009-04-06
EP1412503A2 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
US20090252705A1 (en) IL-6/IL-6R Fusion Protein
Nibbs et al. CC chemokine receptor 3 antagonism by the β-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap
Menten et al. Macrophage inflammatory protein-1
Huang et al. Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils
JP3825255B2 (ja) 炎症媒介物質のアンタゴニスト
JP2000510685A (ja) 単球化学誘引タンパク質１（ｍｃｐ―１）レセプター（ｃｃｒ２）に結合する抗体
AU623698B2 (en) Macrophage-derived inflammatory mediator (mip-2)
JP3051834B2 (ja) 炎症性サイトカインの発生及び／または活性を刺激する薬品の能力を試験する方法
US6117654A (en) Nucleic acid molecules encoding Tango-77-polypeptides
JPH09503232A (ja) ＧＰ１３０結合界面で突然変異したインターロイキン−６（ＩＬ−６）受容体αの可溶性型であるＩＬ−６アンタゴニスト
AU758576C (en) Chemokines with amino-terminal modifications
US6433157B1 (en) Polynucleotides encoding T-cell selective interleukin-4 agonists
US8524656B2 (en) GM-CSF and truncated CCL2 conjugates and methods and uses thereof
JP2007510403A (ja) ケモカイン変異体の治療への使用
AU2002319524A1 (en) A fusion protein
PL204231B1 (pl) Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza
US5965697A (en) Disaggregated mutant human RANTES
US6335426B1 (en) T-cell selective interleukin-4 agonists
TW508356B (en) T-cell selective interleukin-4 agonists
JP2002540068A (ja) 治療におけるｍｉｐ−３ａのアゴニストまたはアンタゴニストの使用
Hussain et al. The Chemokine Receptor CCR8 is Not a High-affinity Receptor for the Human Chemokine CCL18
WO2022020544A1 (en) Method of treating an inflammatory condition
Crisman Identification of amino acids that are responsible for the binding of macrophage inflammatory protein-1-alpha to the CKR1 chemokine receptor
CA2000355A1 (en) Human fc-gamma receptor iii
JPH08103276A (ja) 組換え型ヒト・インターロイキン８レセプター蛋白質、その製造法および用途

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED, GB

Free format text: OLD OWNER(S): UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED; UNIVERSITY OF WALES COLLEGE OF MEDICINE

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: THE PROPRIETOR (71) HAS BEEN CORRECTED

RENW Renewal (renewal fees accepted)
LAPS Patent lapsed